| SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: a cross-sectional study on 916 patients M Zen, E Fuzzi, D Astorri, F Saccon, R Padoan, L Ienna, G Cozzi, ... Journal of autoimmunity 112, 102502, 2020 | 113 | 2020 |
| Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset Still’s disease: a multicentre retrospective observational study S Colafrancesco, R Priori, G Valesini, L Argolini, E Baldissera, E Bartoloni, ... Frontiers in Pharmacology 8, 369, 2017 | 96 | 2017 |
| Autoinflammatory features in gouty arthritis P Galozzi, S Bindoli, A Doria, F Oliviero, P Sfriso Journal of clinical medicine 10 (9), 1880, 2021 | 60 | 2021 |
| Adult-onset Still’s disease: molecular pathophysiology and therapeutic advances P Sfriso, S Bindoli, P Galozzi Drugs 78, 1187-1195, 2018 | 47 | 2018 |
| Sarcoidosis and Autoimmunity: From Genetic Background to Environmental Factors. S Bindoli, A Dagan, JJ Torres-Ruiz, C Perricone, M Bizjak, A Doria, ... The Israel Medical Association Journal: IMAJ 18 (3-4), 197-202, 2016 | 47 | 2016 |
| The amount of cytokine-release defines different shades of Sars-Cov2 infection S Bindoli, M Felicetti, P Sfriso, A Doria Experimental Biology and Medicine 245 (11), 970-976, 2020 | 43 | 2020 |
| Canakinumab for the treatment of adult-onset Still’s disease P Sfriso, S Bindoli, A Doria, E Feist, P Galozzi Expert Review of Clinical Immunology 16 (2), 129-138, 2020 | 41 | 2020 |
| The revisited role of interleukin-1 alpha and beta in autoimmune and inflammatory disorders and in comorbidities P Galozzi, S Bindoli, A Doria, P Sfriso Autoimmunity reviews 20 (4), 102785, 2021 | 39 | 2021 |
| Autoinflammatory mechanisms in crystal-induced arthritis F Oliviero, S Bindoli, A Scanu, E Feist, A Doria, P Galozzi, P Sfriso Frontiers in Medicine 7, 166, 2020 | 24 | 2020 |
| Hyperinflammation after anti-SARS-CoV-2 mRNA/DNA vaccines successfully treated with anakinra: Case series and literature review S Bindoli, A Giollo, P Galozzi, A Doria, P Sfriso Experimental Biology and Medicine 247 (4), 338-344, 2022 | 16 | 2022 |
| Development and role in therapy of canakinumab in adult-onset Still’s disease P Galozzi, C Baggio, S Bindoli, F Oliviero, P Sfriso Frontiers in Pharmacology 9, 407641, 2018 | 16 | 2018 |
| Belimumab: A step forward in the treatment of systemic lupus erythematosus R Depascale, M Gatto, M Zen, F Saccon, M Larosa, E Zanatta, S Bindoli, ... Expert Opinion on Biological Therapy 21 (5), 563-573, 2021 | 15 | 2021 |
| Progress in Biological Therapies for Adult-Onset Still’s Disease P Galozzi, S Bindoli, A Doria, P Sfriso Biologics: Targets and Therapy, 21-34, 2022 | 12 | 2022 |
| Regulation of crystal induced inflammation: current understandings and clinical implications P Galozzi, S Bindoli, R Luisetto, P Sfriso, R Ramonda, A Scanu, F Oliviero Expert Review of Clinical Immunology 17 (7), 773-787, 2021 | 9 | 2021 |
| 18F-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography With Magnetic Resonance for Diagnosing Adult-Onset Still's Disease S Bindoli, P Galozzi, F Magnani, L Rubin, C Campi, A Doria, D Cecchin, ... Frontiers in Medicine 7, 544412, 2020 | 8 | 2020 |
| Intravenous anakinra to curb cytokine storm in adult-onset Still's disease and in macrophage activation syndrome: a case series S Bindoli, P Galozzi, A Doria, P Sfriso Joint Bone Spine 90 (2), 105524, 2023 | 7 | 2023 |
| JAK inhibitors for the treatment of VEXAS syndrome S Bindoli, C Baggio, A Doria, E Bertoldo, P Sfriso Experimental Biology and Medicine 248 (5), 394-398, 2023 | 6 | 2023 |
| New onset and flare of rheumatic diseases following COVID-19 vaccination are mild and respond well to treatment: 9-month follow-up data from a single centre cohort M Gasparotto, S Bindoli, R Padoan, G Cozzi, R Depascale, E Zanatta, ... Clin Exp Rheumatol 41 (3), 642-8, 2023 | 6 | 2023 |
| A pro-inflammatory signature constitutively activated in monogenic autoinflammatory diseases P Galozzi, O Negm, S Bindoli, P Tighe, P Sfriso, L Punzi International Journal of Molecular Sciences 23 (3), 1828, 2022 | 6 | 2022 |
| Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort C Gurnari, MR Pascale, A Vitale, E Diral, A Tomelleri, E Galossi, G Falconi, ... American Journal of Hematology 99 (2), 254-262, 2024 | 5 | 2024 |
